AZDF 265

Drug Profile

AZDF 265

Latest Information Update: 12 Dec 1994

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Boehringer Ingelheim Pharma KG
  • Class Antihyperglycaemics; Benzoic acids
  • Mechanism of Action Potassium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias; Type 2 diabetes mellitus

Most Recent Events

  • 12 Dec 1994 Discontinued-Unspecifed Phase in Arrhythmias in Germany (Transdermal)
  • 12 Dec 1994 Investigation in Type-2 diabetes mellitus in Germany (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top